Mouse Anti-MS4A1 Recombinant Antibody (clone GA101)

RTX or GA101 were added to B-CLL/B-NHL whole blood samples at 100 μg/ml and percentage cell death of neoplastic B cell targets measured by FACS analysis after 4 (black bars) and 24 h (gray bars).

Bologna, L., Gotti, E., Manganini, M., Rambaldi, A., Intermesoli, T., Introna, M., & Golay, J. (2011). Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. The Journal of Immunology, 186(6), 3762-3769.

Percentages of cell death with 100 μg/ml GA101 at 24 h were plotted against CD20 expression levels, measured as number of CD20 molecules/cell, and r² calculated.

Bologna, L., Gotti, E., Manganini, M., Rambaldi, A., Intermesoli, T., Introna, M., & Golay, J. (2011). Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. The Journal of Immunology, 186(6), 3762-3769.

MNC from five normal donors were incubated for 3 h with 10 μg/ml GA101, RTX, or TX and percentage of CD107a expression on CD56+ NK cells analyzed by flow cytometry.

Bologna, L., Gotti, E., Manganini, M., Rambaldi, A., Intermesoli, T., Introna, M., & Golay, J. (2011). Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. The Journal of Immunology, 186(6), 3762-3769.

CD20 molecules do not redistribute tolipid rafts on binding of GA101 and do not colocalizewith CTB-Alexa 488.

Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., ... & Ferrara, C. (2010). Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood, The Journal of the American Society of Hematology, 115(22), 4393-4402.

On binding of GA101 to CD20 in Ramos cells,CD20 is mainly found in the Triton X-100-solublefraction (S) and not in the Triton X-100-insoluble pellet(P) representing lipid rafts (top row). In contrast, bindingof rituximab resulted in the distribution of CD20 into theTriton X-100-insoluble pellet fraction (S; top row). The distribution of Lyn as a typical lipid raft marker and CD71 as a nonlipid raft marker is not affected (bottom2 rows).

Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., ... & Ferrara, C. (2010). Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood, The Journal of the American Society of Hematology, 115(22), 4393-4402.

In the presence of physiologic concentrations of human unspecific IgG (10 mg/mL RedImmune), the type II anti-CD20 antibody GA101 (black) mediates greatly reduced CDC induction compared with rituximab (gray; n=3).

Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., ... & Ferrara, C. (2010). Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood, The Journal of the American Society of Hematology, 115(22), 4393-4402.

Treatment of the aggressive orthotopic disseminated Z138 (MCL) model was initiated 29 days after intravenous injection of tumor cells (n=10 per group). Treatment with 10 mg/kg GA101 (every 7 days, 6 times, intravenously; black line) resulted in increased overall andmedian survival, compared with 10 mg/kg rituximab treatment (dark gray line; P< .008) and vehicle control (light gray line). šindicates the treatment time points.

Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., ... & Ferrara, C. (2010). Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood, The Journal of the American Society of Hematology, 115(22), 4393-4402.